NEXTAR - NEXavar as First TARgeted Treatment for Patients With Advanced Renal Cell Carcinoma

Trial Profile

NEXTAR - NEXavar as First TARgeted Treatment for Patients With Advanced Renal Cell Carcinoma

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Aug 2016

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms NEXTAR
  • Sponsors Bayer
  • Most Recent Events

    • 28 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Jul 2013 New source identified and integrated (German Clinical Trials Register: DRKS00004148).
    • 01 Jul 2013 Planned end date changed from 1 Mar 2015 to 1 Mar 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top